Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Novaliq, following the US and European patent approval, has commenced the Phase I study of CyclASol (Cyclosporin solution) eye drops for the treatment of dry eye syndrome.
Subscribe to our email newsletter
Novaliq claims that CyclASol is the first and only 0.05% clear cyclosporin solution, which is available in multi-dose and preservative free bottles to treat dry eye syndrome.
Developed from Novaliq’s Semi Fluorinated Alkane (SFA) drug delivery platform EyeSol, CyclASol has showed long-term stability plus superior wettability, pharmacokinetics, and biocompatibility compared to conventional emulsions.
The cyclosporin solution offers significant competitive advantages for multiple drug candidates within ophthalmology, primarily by enhancing the therapeutic effect of poorly soluble drugs.
Novaliq CEO Bernhard Günther noted that the company is pleased to receive the US and European patent and to announce the start of Phase I CyclASol study.
"These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio. In 2013 Novaliq finalized their fifth round of financing for €13.9 million ($18.1 million) with the intent to strengthen both their prescription and OTC product development programs based on SFA technology," Günther added.